Niagen Bioscience targets 10–15% revenue growth for 2026 while expanding injectable product line

Q4 2025 earnings call: revenue, margins, 2026 growth guidance, Niagen Plus injection kits, telehealth plans & FDA lawsuit—read now.

Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion

NAD+ company Niagen Bioscience doubles profits in 2025, eyes acquisitions and new markets as the longevity market picks up ...
The Manila Times

Sprout Health NAD+ Injections - Compounding Status, Pharmacy Sourcing, and What Consumers Should Verify Before Any Telehealth NAD+ Enrollment in 2026

Compounded NAD+ Telehealth Access, FDA Classification, Pharmacy Sourcing Standards, Prescription Requirements, and Consumer ...